TANGO 197 and TANGO 216 compositions and methods
OwnerJames B. Rottman, Theresa L. O'Keefe +2inventors
InventorsJames B. Rottman, Theresa L. O'Keefe, Engin Ozkaynak, Judith J. Healey
Life of this patent
Estimating the term…
Abstract
The present application relates, in part, to methods and compositions for the prevention or amelioration of symptoms of anthrax. In particular, the present invention relates to TANGO 197 and/or TANGO 216 fusion polypeptides and their use as part of such methods.
Claims65
A method for preventing a symptom of anthrax in a subject thought to be at risk for exposure to Bacillus anthracis, comprising:
- administering to the subject a pharmaceutically effective amount of a fusion polypeptide so that, if the subject is exposed to Bacillus anthracis, a symptom of said exposure is prevented, wherein said fusion polypeptide comprises a von Willebrand factor A-like domain (vWF) amino acid sequence and an amino acid sequence heterologous to said vWF.
A method for preventing a symptom of anthrax in a subject suspected of having been exposed to Bacillus anthracis, comprising:
- administering to the subject a pharmaceutically effective amount of a fusion polypeptide so that, if the subject has been exposed to Bacillus anthracis, a symptom of said exposure is prevented, wherein said fusion polypeptide comprises a von Willebrand factor A-like domain (vWF) amino acid sequence and an amino acid sequence heterologous to said vWF.
A method for ameliorating a symptom of anthrax in a subject in need of said amelioration, comprising:
- administering to the subject a pharmaceutically effective amount of a fusion polypeptide so that a symptom of anthrax is ameliorated, wherein said fusion polypeptide comprises a von Willebrand factor A-like domain (vWF) amino acid sequence and an amino acid sequence heterologous to said vWF.
A fusion polypeptide comprising a von Willebrand factor A-like domain (vWF) amino acid sequence and an amino acid sequence heterologous to said vWF.
A pharmaceutical composition comprising a fusion polypeptide comprising a von Willebrand factor A-like domain (vWF) amino acid sequence and an amino acid sequence heterologous to said vWF.
Dependencies are inferred from the claim text.